Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ansun, Arvinas, Cytodyn, Gensight, Ico, Mallinckrodt, Oragenics.
In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials.
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd. reported interim data showing that lead candidate paxalisib (formerly GDC-0084) saw a positive overall survival signal in its phase II glioblastoma trial, and the company raised AU$7.2 million (US$4.4 million) days after the data were released.
LONDON – Companies represented in the expert group brought together by the World Health Organization (WHO) to work on the development of COVID-19 vaccines have signed a pledge to strengthen collaboration and sharing of data.
New York-based Immunovant Inc.’s phase IIa results with neonatal Fc receptor (FcRn)-targeting IMVT-1401 in thyroid eye disease (TED), also known as Graves’ ophthalmopathy, prompted renewed speculation about the space, hot since the approval on Jan. 21 of Tepezza (teprotumumab-trbw) from Horizon Therapeutics plc, of Dublin.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Amgen, Astrazeneca, Beigene, Bioinvent, Calithera, Cytokinetics, Healios, Madrigal, Outlook.
In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials. But patients still in the studies need to be followed for safety and efficacy, creating challenges for the industry.
Stony Brook Medicine has launched an FDA-approved, randomized investigational new drug (IND) trial to determine whether plasma from people who have recovered from COVID-19 can aid in the recovery of patients currently fighting the disease. Chembio Diagnostics Inc.'s COVID-19 rapid serological point-of-care test will be used to identify potential plasma donors.
The human body constantly assaults medical devices that are implanted within it. The traditional solution to that has been to encase them in titanium. But that’s not the best option in the brain, where it remains difficult to place a high number of electrodes without damaging the brain, while protecting the device from long-term damage.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, Aslan, Bausch Health, Kolon, Lilly, Nextcure, Prolynx.
RSS
